SLU-PP-332 5mg

SLU-PP-332 is an experimental small molecule designed as a potent ERR (estrogen-related receptor) agonist. By targeting ERR pathways, it has shown potential to enhance mitochondrial activity, energy expenditure, and endurance capacity. While still under preclinical investigation, SLU-PP-332 represents a promising therapeutic candidate for metabolic health and performance.

• Mitochondrial Support: Enhances oxidative metabolism and energy efficiency.

• Improved Endurance: Preclinical studies suggest greater exercise tolerance and stamina.

• Metabolic Enhancement: May promote fat utilization and glucose regulation.

• Research Tool: Valuable for exploring novel ERR-targeted therapies.

• Preclinical animal studies show increased aerobic capacity and mitochondrial biogenesis.

• Early research indicates potential applications in metabolic disorders and performance enhancement.

• No human clinical data yet available — ongoing evaluation in laboratory research.

• Safety data currently limited to preclinical models.

• No established adverse event profile in humans.

• Further investigation required before clinical translation.